Clinical Trial Update: Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intravenous decitabine in combination with oral bexarotene for acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dacogen (decitabine)
• Targretin (bexarotene)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: COMPLETED